Search
Cardiolipin Biosynthesis CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z)/18:0)
smpdb.ca/view/SMP0287947MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
Cardiolipin Biosynthesis CL(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(11Z,14Z,17Z))
smpdb.ca/view/SMP0495572MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
Cardiolipin Biosynthesis CL(14:0/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
smpdb.ca/view/SMP0495575MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
Descartes-30
go.drugbank.com/drugs/DB16361InvestigationalDescartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics.
Synonyms: Descartes 30Cefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigational[A189150] A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined. … Cefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019.
Dichlorobenzyl alcohol
go.drugbank.com/drugs/DB13269Approved[A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.
Indalpine
go.drugbank.com/drugs/DB08953ApprovedWithdrawnIndalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. … However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsProhibitin-2
go.drugbank.com/bio_entities/BE0009007TargetHumansProtein with pleiotropic attributes mediated in a cell-compartment- and tissue-specific manner, which include the plasma membrane-associated cell signaling functions, mitochondrial chaperone, and transcriptional co-regulator of transcrip...
Synonyms: BAPTaurochenodeoxycholic acid
go.drugbank.com/drugs/DB08833ExperimentalAs a medication, taurochenodeoxycholic acid reduces cholesterol formation in the liver, and is likely used as a choleretic to increase the volume of bile secretion from the liver and as a cholagogue to … Its physiologic function is to emulsify lipids such as cholesterol in the bile.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigationalOn February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).